Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Togashi

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Cancer Research|January 13, 2025
Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination ImmunotherapyToshifumi Ninomiya, Naoya Kemmotsu, Fumiaki Mukohara, et al.
Cancer Science|February 27, 2026
TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung CancerTadahiro Kuribayashi, Jun Nishimura, Sachi Okawa, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve <i>Egfr</i>-Mutant Lung Cancer with Non-Inflamed Tumor MicroenvironmentAtsuko Hirabae, Tadahiro Kuribayashi, Shuta Tomida, et al.
International Journal of Cancer|August 23, 2023
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapiesNaoya Kemmotsu, Kiichiro Ninomiya, Kei Kunimasa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2020
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)Shota Fukuoka, Hiroki Hara, Naoki Takahashi, et al.
Molecular Cancer Therapeutics|September 26, 2014
MEK inhibitor for gastric cancer with MEK1 gene mutationsShunsuke Sogabe, Yosuke Togashi, Hiroaki Kato, et al.
Molecular Carcinogenesis|February 27, 2016
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapiesTakuro Mizukami, Yosuke Togashi, Saeko Naruki, et al.
BMC Cancer|April 22, 2020
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinomaHideaki Bando, Daisuke Kotani, Takahiro Tsushima, et al.
Lung Cancer (Amsterdam, Netherlands)|July 12, 2020
Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinomaKei Sato, Sachiyo Mimaki, Riu Yamashita, et al.
Cancer Immunology Research|July 1, 2025
Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor ImmunityYuto Naoi, Yumi Inukai, Tomoka Izumikawa, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Cancer Research|January 13, 2025
Myeloid Cells Induce Infiltration and Activation of B Cells and CD4+ T Follicular Helper Cells to Sensitize Brain Metastases to Combination ImmunotherapyToshifumi Ninomiya, Naoya Kemmotsu, Fumiaki Mukohara, et al.
Cancer Science|February 27, 2026
TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung CancerTadahiro Kuribayashi, Jun Nishimura, Sachi Okawa, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Naïve <i>Egfr</i>-Mutant Lung Cancer with Non-Inflamed Tumor MicroenvironmentAtsuko Hirabae, Tadahiro Kuribayashi, Shuta Tomida, et al.
International Journal of Cancer|August 23, 2023
Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapiesNaoya Kemmotsu, Kiichiro Ninomiya, Kei Kunimasa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2020
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)Shota Fukuoka, Hiroki Hara, Naoki Takahashi, et al.
Molecular Cancer Therapeutics|September 26, 2014
MEK inhibitor for gastric cancer with MEK1 gene mutationsShunsuke Sogabe, Yosuke Togashi, Hiroaki Kato, et al.
Molecular Carcinogenesis|February 27, 2016
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapiesTakuro Mizukami, Yosuke Togashi, Saeko Naruki, et al.
BMC Cancer|April 22, 2020
TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinomaHideaki Bando, Daisuke Kotani, Takahiro Tsushima, et al.
Lung Cancer (Amsterdam, Netherlands)|July 12, 2020
Association between the mutational smoking signature and the immune microenvironment in lung adenocarcinomaKei Sato, Sachiyo Mimaki, Riu Yamashita, et al.
Cancer Immunology Research|July 1, 2025
Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor ImmunityYuto Naoi, Yumi Inukai, Tomoka Izumikawa, et al.
Pageof 16